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Abstract
Influenza viruses are among the most important human pathogens and are responsible for annual epidemics and sporadic,
potentially devastating pandemics. The humoral immune response plays an important role in the defense against these
viruses, providing protection mainly by producing antibodies directed against the hemagglutinin (HA) glycoprotein.
However, their high genetic variability allows the virus to evade the host immune response and the potential protection
offered by seasonal vaccines. The emergence of resistance to antiviral drugs in recent years further limits the options
available for the control of influenza. The development of alternative strategies for influenza prophylaxis and therapy is
therefore urgently needed. In this study, we describe a human monoclonal antibody (PN-SIA49) that recognizes a highly
conserved epitope located on the stem region of the HA and able to neutralize a broad spectrum of influenza viruses
belonging to different subtypes (H1, H2 and H5). Furthermore, we describe its protective activity in mice after lethal
challenge with H1N1 and H5N1 viruses suggesting a potential application in the treatment of influenza virus infections.
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Introduction
Seasonal influenza causes up to 500,000 deaths worldwide each
year [1]. Infants, immunocompromised individuals and the elderly
are particularly susceptible, with 90% of deaths occurring in the
latter group [2]. Influenza viruses can also cause pandemics that,
although rare, are recurrent events historically associated with
high levels of morbidity and mortality [3,4,5,6]. Preventive
vaccination has historically been the most efficient measure of
influenza control, but this approach presents important limitations
due to the accumulation of antigenic mutations in the virus, known
as antigenic drift. Vaccines typically elicit a potent neutralizing
antibody response limited to the specific viral strains included in
the preparation and to closely related viruses [2]. For this reason,
seasonal vaccines need to be annually reformulated based upon
the forecasting of viral strains that will circulate in the coming
influenza season. Furthermore, influenza vaccines have subopti-
mal immunogenicity and efficacy in the groups at highest risk of
severe disease [7]. Moreover in the case of a pandemic, the use of
vaccine is limited by the time required for its development and
deployment [8].
The current therapeutic regimen for influenza A viruses is
limited to two classes of drugs: the adamantanes (amantadine and
rimantadine) and the neuraminidase inhibitors (oseltamivir and
zanamivir). However, the natural and/or acquired resistance to
these drugs has been reported [9,10]. Resistance to adamantanes is
prevalent among seasonal and avian influenza A viruses
significantly reducing their usefulness [11,12]. The sudden and
widespread emergence of resistance to oseltamivir among pre-
pandemic H1N1 viruses has raised further concerns over the
current therapeutic options [13,14]. Oseltamivir resistance was
reported in patients infected with the pandemic H1N1 viruses and
highly virulent H5N1 viruses [15,16]. The resistance to zanamivir
is rare [17], but its use is limited to patients who can actively inhale
it, which often excludes young children, impaired older adults or
patients with underlying airway disease [14], that is the groups of
patients most vulnerable to serious influenza infection complica-
tions.
Alternative strategies are needed to combat the constant threats
posed by influenza. One of such strategies may come from passive
immunoprophylaxis with monoclonal antibodies (mAbs) recogniz-
ing broadly conserved influenza epitopes and endowed with
broad-range neutralizing activity [18].
The most important protective antigen on the surface of
influenza virus is HA, whose structure can be divided in two
distinct regions: the globular head, responsible for the binding to
the sialic acid, and the stem region that contains the fusion peptide
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constituted by the HA1 subunit, lie several epitopes targeted by
neutralizing antibodies [18]. However, mAbs recognizing this
region are of restricted application due to the antigenic drift that
this region encounters [18]. In contrast, the stem region of HA,
formed mostly by the HA2 subunit, is relatively conserved among
different influenza A subtypes [19] and indeed could represent an
universal target for the development of cross-neutralizing mono-
clonal antibodies.
Several human heterosubtypic neutralizing mAbs, directed
against HA stem region and with protective features in animal
models, have been recently described [20,21,22,23,24,25] . All
these mAbs recognize epitopes located in the most conserved
region of influenza viruses HA and neutralize influenza viruses by
blocking fusion of the viral and the host endosomal membranes.
Many of these anti-influenza heterosubtypic neutralizing mAbs
utilize the VH1-69 germline gene and bind to a hydrophobic
region on the HA stem using their complementary determining
region 2 (CDR2).
In this study, we describe a human monoclonal antibody named
PN-SIA49 recognizing a highly conserved epitope on the stem
region of HA and featuring one of the strongest in-vitro
neutralizing activity described so far against a broad spectrum of
viruses belonging to different influenza subtypes (H1, H2 and H5).
Furthermore, we describe its protective activity in mice after lethal
challenges with H1N1 and H5N1 viruses suggesting its potential as
a broad-spectrum monoclonal antibody for treatment of influenza
virus infection.
Results
Heterosubtypic neutralization of influenza virus subtypes
by PN-SIA49
It was previously described that the Fab fragment of PN-SIA49
binds to the stem region of HA and neutralizes all tested H1N1
isolates [26,27]. The heavy chain variable region of PN-SIA49
uses the VH3-23 gene and is paired with a VL1-39 light chain.
The nucleotide sequence homology of PN-SIA49 with the
germline sequence is 93.11% for the VH gene and 92.30% for
the VL gene, demonstrating its origin from a somatic mutation
process.
In this study, in order to better characterize its neutralizing
activity, PN-SIA49 was produced as whole IgG1 molecule using
the BD BaculoGold System. The whole IgG molecule was tested
in fluorescence inhibition assay, infectious foci formation reduction
assay and plaque reduction assay against human, swine and avian
influenza A viruses belonging to phylogenetic group 1 (H1N1,
H2N2, H5N1 and H9N2) and group 2 (H3N2 and H7N2). The
results obtained showed that IgG PN-SIA49 has a stronger
neutralizing activity compared to Fab PN-SIA49 (Table 1) [26,27].
Indeed, IgG PN-SIA49 neutralized all tested viruses belonging to
group 1, except the virus strain belonging to H9N2 subtype, with a
half maximal inhibitory concentration (IC50) ranging between
0.1–1.9 mg/ml (Table 1 and Figure S1). On the contrary, PN-
SIA49 showed no neutralizing activity against the viruses
belonging to group 2 (Figure S2). These data suggest that the
epitope recognized by PN-SIA49 is conserved among group 1
viruses.
Therapeutic efficacy of PN-SIA49 against H1N1 and H5N1
challenge in a mouse model
To determine whether the in-vitro neutralizing activity
displayed by PN-SIA49 would be predictive of its protective
efficacy in-vivo, BALB/c mice were inoculated intranasally with 3
fifty percent lethal dose (LD50) of A/Wilson Smith/33(H1N1)
(WS33) or A/Vietnam/1203/2004 (H5N1) (VN04) virus, and
were treated 24 hours later with 10, 1 or 0.1 mg/kg of PN-SIA49.
An anti-HCV/E2 mAb (e137) [28] was used as control at 10 mg/
kg. PN-SIA49 protected mice from lethal challenge with WS33 in
a dose-dependent manner providing 100% protection (6/6)
against death in animals that received 10 mg/kg of the antibody
and 83.3% protection (5/6) in animals that received 1 mg/kg
(Figure 1C). Consistent with the in-vitro neutralizing activity, PN-
SIA49 at 10 mg/kg afforded 66.6% protection against lethal
H5N1 virus challenge (Figure 1D) whereas control mice rapidly
succumbed to infection by day 8 post-challenge (p.c.). Surviving
mice remained healthy and showed minimal body weight loss
(maximum weight loss: 7.2% in WS33 group, 14.4% in VN04
group) over the 2-week observation period. At the conclusion of
the experiment, The mean body weight loss was 2.2% in the
treated mice challenged with VN04 virus (Figure 1B) while mice
infected with WS33 regained their full body weight (Figure 1A).
To gain further insights into the kinetics of viral neutralization
in vivo, 4 mice from each group were euthanized on day 4 p.c. and
viral titer was determined in whole lung tissues. PN-SIA49
significantly reduced virus titer in the lungs of mice infected with
WS33 by approximately 2,000 fold at 10 mg/kg and about 700
fold at 1 mg/kg (Figure 1E). A 10-fold reduction in pulmonary
virus titer was noted in mice challenged with VN04 virus that
received PN-SIA49 at 10 mg/kg (Figure 1F).
Taken together, these results indicate that the survival was
associated with an important reduction of the virus burden in the
lungs of mice treated with PN-SIA49 and that the reduction is
concordant with its in-vivo activity.
Definition of the region bound by PN-SIA49 on HA
In order to better define the HA region recognized by PN-
SIA49, several approaches were used.
Firstly, the hemagglutination inhibition (HI) activity for PN-
SIA49 was evaluated and the resulting HI titre was 2.5 mg/ml and
0.039 mg/ml for VN04 and WS33 virus, respectively.
Secondly, to evaluate if PN-SIA49 recognizes an epitope on the
HA stem region, a competition assay on A/Puerto Rico/8/1934-
HA (A/PR/8/34-HA) human epithelial kidney HEK293T
transfected cells was performed between PN-SIA49 and the
commercially available mouse monoclonal antibody C179 (Takara
Bio inc., Otsu, Shiga, Japan), which binds to an epitope on the HA
stem region [29]. The results obtained showed that PN-SIA49
completely inhibited C179 binding to the A/PR/8/34-HA (Figure
S3).
Further evidence that PN-SIA49 binds to an epitope on the HA
stem region is given by lack of protease susceptibility of the HA at
low pH in the presence of PN-SIA49. Exposure to low pH
followed by trypsin digestion results in degradation of HA. In
contrast, when the HA is pre-treated with PN-SIA49, most HA is
retained in a protease resistant, pre-fusion form (Figure 2).
Taken together, these preliminary data suggest that the epitope
recognized by PN-SIA49 is localized in the HA stem region, but in
close proximity of the HA globular head.
Based on the PN-SIA49-C179 competition assay results, a large
panel of HA mutants carrying an alanine substitution were
generated [29,30,31,32]. The binding of PN-SIA49 to these
mutants was then evaluated by FACS analysis. Data obtained
revealed that the binding of PN-SIA49 was decreased by
His25Ala, Asn336Ala, Pro338Ala mutants on HA1 and Me-
t360Ala, Asp362Ala, Gly363Ala, Trp364Ala, Thr384Ala, Va-
l395Ala, Asn396Ala, Glu400Ala mutants located on HA2
(sequence numbering refers to A/PR/8/34, GenBank accession
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conserved among viruses belonging to H1N1 subtype spanning
from 1918 and 2009 and also highly conserved in H2N2 and
H5N1 subtypes (Figure 3). All the other mutations did not have
any effect on the antibody PN-SIA49 binding to the HA (Figure 3).
To exclude the possiblity that the reduced PN-SIA49 binding to
HA was due to reduced expression of HA on the cell surface, we
performed a FACS analysis in which wild-type HA and mutants
HA were stained with a mouse anti-influenza A HA (H1 subtype)
monoclonal antibody. This antibody was directed against a linear
epitope in order to evaluate the expression level for each HA on
cell surface. As shown in figure S4, the HA mutants are expressed
on the cell surface at a similar levels to that of wild type HA.
Consistent with the great phylogenetic distance, the amino
acidic difference in positions 25, 360 and 362 between the tested
viral strains belonging to H1N1, H2N2, H5N1 subtypes and the
viral strains belonging to H9N2 subtype may at least partially
explain the lack of neutralizing activity against the H9N2 strain.
Based on the results obtained from the alanine scanning study,
an in-silico analysis on the HA crystal structure of A/PR/8/34
(PDB ID code 1RU7) was carried out. The analysis confirmed that
the residues identified lie on the stem region of HA, that they
belong to the HA1 and HA2 subunits and that they are exposed
on the surface of the HA molecule (Figure 4).
Discussion
In this study, we characterize a human mAb, IgG PN-SIA49,
directed against influenza viruses and previously described as Fab
fragment [26,27]. IgG PN-SIA49 neutralizes a broad spectrum of
viruses belonging to different influenza subtypes (H1, H2 and H5)
and is characterized by the lowest mean IC50 values described to
date for a heterosubtypic mAb [20,21,22,23,24,25] against the
influenza subtypes tested in this study (Table S1). Furthermore, IgG
PN-SIA49 is endowed with a stronger neutralizing activity
compared to its monovalent molecule (Table 1). Indeed, it is well
documented in the literature that bivalency of IgG molecule may be
an essential feature for the biological activity of a mAb, mostly due
to an increase in antibody avidity [33,34,35,36]. The increased
avidity may also play an important role in the prophylactic and
therapeutic application of an antibody, allowing the administration
of smaller amount compared to the Fab fragment. Additionally, the
whole IgG molecule has a longer half-life than its fragments, with a
consequent prolonged effect of the molecule. For all these reasons,
we used IgG PN-SIA49 to treat mice infected with H1N1 and
H5N1 viruses and data obtained show that PN-SIA49 protects mice
from H1N1 and H5N1 virus lethal challenge suggesting its potential
application in treatment of influenza virus infections.
Most of the anti-influenza heterosubtypic neutralizing mAbs
described thus far, derived from the VH1-69 germline, bind to a
conserved epitope in the HA stem region present only on group 1
influenza A viruses. The binding is mainly through highly
hydrophobic amino acidic residues in the heavy chain CDR2
[20,21,22,23,24,25]. Instead, the heavy chain variable region of
PN-SIA49 results from VH3-23 gene rearrangement with the D3-
3 and JH6 gene segments demonstrating that, despite the
preferential usage of VH1-69 in the heterosubtypic response to
influenza HA [20], an in-vivo heterosubtypic protection may be
conferred also by non VH1-69 derived Abs.
PN-SIA49 recognizes a novel broadly neutralizing epitope on
HA stem region, which is highly conserved among group 1
subtypes that have been confirmed in humans. In particular, this
region is broadly shared among H1N1 isolates spanning from
1918 to 2009, H2N2 subtype responsible for the 1957 pandemic,
Table 1. PN-SIA49 neutralizing activity against all tested influenza strains.
Subtype Strain Fab PN-SIA49 IgG PN-SIA49
IC50
a mg/ml IC50a mg/ml
H1N1 A/Wilson Smith/1933 4.5 0.5
A/Puerto Rico/8/1934 2.1 0.4
A/Malaya/302/1954 2.7 0.2
A/Milan/UHSR1/2009 2.8 0.1
A/swine/Parma/1/1997 2.3 1.1
H2N2 A/Ann Arbor/6/1960 ND
b 1.1
H5N1 A/Vietnam/1203/2004 clade 1 ND 1.1
A/duck/Vietnam/NCVD98/2007 clade 2.3.4 ND 1.9
H9N2 LAIV A/chicken/Hong Kong/G9/1997 ND .10
H3N2 A/Aichi/2/1968 ND .20
A/Hong Kong/8/1968 ND .30
A/Port Chalmers/1/1973 ND .20
A/Philippines/01/1982 ND .10
A/England/648/1989 ND .10
A/Fukui/20/2004 ND .10
A/Washington/01/2007 ND .30
A/New Hampshire/01/2009 ND .30
H7N2 A/New York/107/2003 ND .10
aIC50: Half maximal inhibitory concentration expressed in mg/ml.
bND: not determined.
doi:10.1371/journal.pone.0034415.t001
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virus.
Finally, PN-SIA49 is protective in mice when given after lethal
challenge with either H1N1 or H5N1 virus. This suggests its great
potential as broad-spectrum monoclonal antibody for in vivo
treatment of influenza virus infections.
Taken together, these data underline the importance of PN-
SIA49 for the development of anti-influenza strategies based on
passive immunization. Further studies will be necessary to define
the most effective prophylactic and therapeutic administration
protocols. Finally, these data and a more detailed definition of the
epitope recognized by PN-SIA49 could also be useful to develop
new vaccination strategies able to elicit a humoral immune
response directed against key regions of the influenza HA protein.
Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Figure 1. PN-SIA49 confers protection in mice against lethal challenge with both A/Wilson Smith/33 and A/Vietnam/1203/2004.
Female BALB/c mice were challenged with 3 LD50 of A/Wilson Smith/33 (WS33) or A/Vietnam/1203/2004 (VN04). Twenty-four hours after the viral
challenge, graded doses (10, 1, 0.1 mg/Kg) of PN-SIA49 or the control antibody (e137, 10 mg/Kg) were administrated to mice. Mice were monitored
for body weight loss and survival for 2 weeks after challenge. (A) Body weight following WS33 virus challenge and (B) VN04 and treated with PN-
SIA49. (C) Survival rates of mice challenged with WS33 and (D) VN04 after PN-SIA49 treatment. (E) Viral titers in the lungs of mice challenged with
WS33 and (F) VN04 on day 4 post infection. Each data point represents the average viral titer from 4 mice. A group of mice treated with a negative
control mAb (e137) was used and is included in each panel for direct comparison.
doi:10.1371/journal.pone.0034415.g001
Protective Anti-Influenza Human mAb
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2011). All mouse procedures were approved by Institutional
Animal Care and Use Committee (IACUC) of the Centers for
Disease Control and Prevention and performed in accordance
with the IACUC guidelines (Protocol # 1619: ‘‘Studies on the
Pathogenesis of and Immunity to Influenza Viruses in Mice’’).
Figure 2. PN-SIA49 protects H1-HA from the low pH induced protease sensitivity. Western Blotting results of the protease susceptibility
assay for H1-HA. Exposure to low pH converts HA to the protease-susceptible, post-fusion state (lane 6 and 7). Pre-treatment with PN-SIA49 partially
blocks the pH-induced conformational change retaining HA in the protease-resistant, pre-fusion state (lane 3 and 4). In lanes 2–4 is also visible the
signal given by PN-SIA49 (180 KDa). The other bands (about 110 KDa and 190 KDa) are due to HA aggregates bound by PN-SIA49 or by the primary
anti-influenza Ab used in the western blotting assay.
doi:10.1371/journal.pone.0034415.g002
Figure 3. Amino acidic sequence conservation in hemagglutinin groups and subtypes at the region bound by PN-SIA49. Circles
below residues indicate PN-SIA49 percentage binding to each HA alanine mutant compared to binding to the wild-type HA: red 25% binding; yellow
50–75% binding, blue 100% binding. Sequence numbering is based on H1N1 A/Puerto Rico/8/1934 coding region (GenBank accession number
ABO21709). Subtypes that can be neutralized by PN-SIA49 are indicated with a green ‘+’ on the left, while the ones that can not be neutralized are
indicate with a red ‘2’.
a Recombinant HA from H1N1 A/South Carolina/1/1918 pandemic strain was previously shown to be bound by PN-SIA49
[26,27].
b H1N1 A/New Caledonia/20/1999 was previously shown to be neutralized by PN-SIA49 as Fab fragment [26,27].
doi:10.1371/journal.pone.0034415.g003
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We previously described the molecular cloning of a human
monoclonal antibody Fab fragment named PN-SIA49 [26,37].
The whole antibody molecule was obtained using the BD
BaculoGold System (BD Biosciences Pharmingen, San Diego,
CA, USA). Briefly, nucleotide sequences codifying heavy and light
chains of the PN-SIA49 Fab fragment were cloned into the
baculovirus expression vector pAc-k-Fc (PROGEN Biotechnik
GmbH, Heidelberg, Germany). Sf9 insect cells (Invitrogen,
Carlsbad, CA, USA) were co-transfected with the linearized
baculovirus DNA (BD Biosciences Pharmingen, San Diego, CA,
USA) and the pAc-k-Fc/PN-SIA49. The obtained virus was
inoculated at a multiplicity of infection (MOI) of 5 to infect 16109
High Five insect cells (Invitrogen, Carlsbad, CA, USA) in a final
volume of 1 liter. After an incubation of 96 hours the culture
media was collected, clarified by centrifugation and filtered with
0.2 mm filter (Millipore, Billerica, MA, USA). The media was
loaded into a protein G column (Amersham Biosciences GE
Healthcare, Zurich, Switzerland), the antibody was eluted with
citric acid 0.1 M, pH 3, and immediately neutralized with Tris
Base 1 M, pH 9. The solution containing the antibody was
dialyzed against PBS and then concentrated using Amicon Ultra-
15 Centrifugal Filter Devices (Millipore, Billerica, MA, USA).
Antibody concentration was determined by SDS-PAGE gel and by
spectrophotometric measurement at 280 nm.
An anti-influenza A antibody directed against H1N1 subtype
HA, named RB62, and an anti-HCV E2 glycoprotein antibody,
named e137 [28], produced and purified with an identical
procedure were used as controls in all experiments.
Viruses and cells
The following human H1N1 and H3N2 reference strains were
acquired from the American Type and Culture Collection
(ATCC): A/Puerto Rico/8/1934 (H1N1) (ATCC n. VR-1469);
A/Wilson Smith/1933 (H1N1) (ATCC n. VR-1520); A/Malaya/
302/1954 (H1N1) (ATCC n. VR-98); A/Hong Kong/8/1968
(H3N2) (ATCC n. VR-544); A/Aichi/2/1968 (H3N2) (ATCC n.
VR-547); A/Port Chalmers/1/1973 (H3N2) (ATCC n. VR-810).
The swine origin influenza virus (S-OIV) A/Milan/UHSR1/2009
(H1N1v) was previously isolated in our laboratory [26,37]. A swine
strain, A/swine/Parma/1/1997 (H1N1), was kindly provided by
the Zooprophylactic Institute of Brescia, Italy. All these viruses
were tested in the BLS3 laboratory of the Vita-Salute San Raffaele
University. The following H1N1, H2N2, H3N2, H5N1, H7N2
and H9N2 viruses were tested at the Centers for Disease Control
and Prevention (CDC) of Atlanta, Georgia, USA: A/Wilson
Smith/1933 (H1N1); A/Ann-Arbor/6/1960 (H2N2); A/Hong
Kong/8/1968 (H3N2); A/Pilippines/01/1982 (H3N2); A/En-
gland/648/1989 (H3N2); A/Fukui/20/2004 (H3N2); A/Wash-
ington/01/2007 (H3N2); A/NewHampshire/01/2009 (H3N2);
A/Vietnam/1203/2004 (H5N1) clade 1; A/duck/Vietnam/
NCVD98/2007 (H5N1) clade 2.3.4; A/New York/107/2003
(H7N2); LAIV A/chicken/Hong Kong/G9/1997 (H9N2).
All viruses, excluding the A/swine/Parma/1/1997, were
cultured on Madin-Darby Canine Kidney (MDCK) (ATCC
CCL-34) cells propagated in Modified Eagle Medium (MEM)
(Gibco Invitrogen, Carlsbad, CA, USA) supplemented with 2%
bovine serum albumin (Gibco Invitrogen, Carlsbad, CA, USA),
50 mg/ml of penicillin (Gibco Invitrogen, Carlsbad, CA, USA),
100 mg/ml of streptomycin (Gibco Invitrogen, Carlsbad, CA,
USA) and 2 mg/ml TPCK–trypsin (Roche Applied Science). The
A/swine/Parma/1/97 isolate was analogously grown on Newborn
Swine Kidney (NSK) cells, kindly provided by the Zooprophylactic
Institute of Brescia, Italy. At 80% confluence, cells in MEM
supplemented with 2 mg/ml serum-free TPCK-trypsin, were
infected with each strain at a MOI of 0.001. After 1 hour of
infection, cells were washed with phosphate buffered saline (PBS);
MEM supplemented with 2 mg/ml TPCK-trypsin was then added
and cells were incubated at 37uC in 5% CO2 atmosphere. Cells
were observed daily to monitor the cytopathic effect and, usually
after 72–96 hours, the supernatant was collected, centrifuged at
1000 rcf for 10 minutes to eliminate cells debris and filtered with
0.22 mm filters (Millipore, Billerica, MA, USA). The supernatant
was then aliquoted and stored at 280uC as cell-free virus.
Virus neutralization assays
Fluorescence inhibition assay and plaque reduction
assay. The following H1N1 and H3N2 viruses were tested
using the fluorescence inhibition assay: A/Puerto Rico/8/1934
(H1N1); A/Wilson Smith/1933 (H1N1); A/Malaya/302/1954
(H1N1); A/Milan/UHSR1/2009 (H1N1v); A/swine/Parma/1/
1997 (H1N1); A/Hong Kong/8/1968 (H3N2); A/Aichi/2/1968
(H3N2); A/Port Chalmers/1/1973 (H3N2). Each viral isolate was
titrated by the limiting dilution method and the viral titer
calculated by the Reed-Muench formula. Neutralizing assays
were carried out in 96 wells plate using MDCK cells (46104cells/
Figure 4. Amino acidic residues involved in the binding of PN-
SIA49 to A/Puerto Rico/8/1934 (H1N1) hemagglutinin. The HA of
A/Puerto Rico/8/1934 is represented as trimer with the HA1 domains
colored white and the HA2 domains colored cyan. Mutations that affect
the binding of PN-SIA49 are highlighted in red.
doi:10.1371/journal.pone.0034415.g004
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were preincubated for 1 hour at 37uC with 100 median tissue
culture infective doses (TCID50) of virus. Following incubation,
100 ml of the mix antibody-virus were added to the cells and
incubated for another hour at 37uC in 5% CO2. At the end of this
incubation, cells were washed with PBS and 100 ml of MEM
TPCK-Trypsin (2 mg/ml) were added in each well. Cells were
incubated for 7 hours at 37uC in 5% CO2 and then washed with
PBS, fixed and permeabilized with ice-cold ethanol. Cells were
incubated with anti-influenza A mouse antibody (Argene, Shirley,
NY, USA) for 30 minutes at 37uC in a humid chamber. The cells
were then washed with PBS and incubated for 30 minutes at 37uC
in a dark humid chamber with a FITC-conjugated secondary
antibody (Argene, Shirley, NY, USA). Nuclei staining was
obtained with Hoechst 33342 (Sigma Aldrich). An infection
control without antibody was included, as well as a negative
control with the anti-HCV/E2 antibody e137. Each neutralization
assay was performed in triplicate and repeated in two different
sessions.
The neutralization activity for each antibody concentration was
expressed as the percentage reduction of fluorescent nuclei
compared with the nuclei count in the infection control. Nuclei
counting was performed by using the GE Healthcare’s IN Cell
Analyzer 1000, an automated epifluorescence based microscope
system. The neutralization curves were then fit by non-linear
regression with the GraphPad Prism software, allowing IC50
calculation.
The A/PR/8/34 (H1N1) and A/Milan/UHSR1/2009 (H1N1)
viruses were also tested in plaque reduction assay as previously
described [26]. Briefly, neutralizing assays were carried out in 6
wells plates using MDCK cells (56105 cells/well). Two dilutions,
1-0.1 mg/ml, of IgG PN-SIA49 were preincubated for 1 hour at
37uC with 100 TCID50 of virus. Following this incubation, 1 ml
of each virus-antibody mix was added on MDCK monolayer and
the plate was incubated 1 hour at 37uC in 5% CO2. Then, the
medium was removed and the monolayer washed twice with PBS.
Two ml of MEM-agarose 0.8% supplemented with penicillin
(50 mg/ml) (Gibco Invitrogen, Carlsbad, CA, USA), streptomycin
(100 mg/ml) (Gibco Invitrogen, Carlsbad, CA, USA), L-glutamine
(2 mM) (Gibco Invitrogen, Carlsbad, CA, USA) and trypsin
(2 mg/ml) (Roche Applied Sciences) were added to each well and
the plates were incubated 48 hours at 37uC in 5% CO2. After this
incubation, the agarose medium was removed from each well and
1 ml of 70% methanol-crystal violet 1% (w/v) was added to each
well at room temperature. Finally, the wells were washed with tap
water and dried. An infection control without antibody was added
as well as a negative control with anti-HCV/E2 e137 mAb. The
neutralization was determined counting the PFU reduction in
presence of antibodies compared to the infection control.
Infectious foci formation reduction assay. The following
H1N1, H2N2, H3N2, H5N1, H7N2 and H9N2 viruses were
tested: A/Wilson Smith/1933 (H1N1); A/Ann-Arbor/6/1960
(H2N2); A/Hong Kong/8/1968 (H3N2); A/Pilippines/01/1982
(H3N2); A/England/648/1989 (H3N2); A/Fukui/20/2004
(H3N2); A/Washington/01/2007 (H3N2); A/NewHampshire/
01/2009 (H3N2); A/Vietnam/1203/2004 (H5N1) clade 1; A/
duck/Vietnam/NCVD98/2007 (H5N1) clade 2.3.4; A/New
York/107/2003 (H7N2); LAIV A/chicken/Hong Kong/G9/
1997 (H9N2). Each viral isolate was titrated to establish working
dilution that produces 15-30 foci forming units per well in 96 tissue
culture plates. Neutralizing assays were carried out in 96 wells
plate using MDCK/SIAT-1 cells. Serial dilutions, 30 mg/ml-
0.37 mg/ml, of IgG PN-SIA49 were preincubated for 1 hour at
37uC with the subset of viruses. Following this incubation, 100 ml
of the antibody-virus mix was added to the cells and incubated for
another hour at 37uC in 5% CO2. At the end of this incubation,
the cells were washed twice in PBS and 100 ml of virus growth
media containing 2 mg/ml of TPCK treated trypsin was added.
Cells were incubated for 12–16 hours at 37uC in 5% CO2 and
then washed with PBS, fixed and permeabilized with ice cold
methanol/acetic acid (95:5) for 30 min at 220uC. Cells were
incubated with anti-NP antibodies (Millipore, Billerica, MA, USA)
for 30 minutes at 37u. The cells were then washed and incubated
for 30 minutes at 37uC with a mouse HRP-conjugated secondary
antibody. True Blue chromogenic substrate (KPL) was used to
count the number of foci.
Murine lethal challenge models
Female BALB/c mice were purchased at 6 to 8 weeks of age
from Charles River Co. (Wilmington, MA). All mice were
maintained in specific pathogen–free barrier facilities. All animal
experiments and procedures conformed to protocols approved by
the Centers for Diseases Control and Prevention (CDC), Atlanta,
GA, USA.
For each virus, four groups of 10 mice were inoculated
intranasally with 3 LD50 of A/Wilson Smith/33 or A/
Vietnam/1203/2004 virus in a 50 ml volume. At 24 h after
inoculation, graded doses (10, 1, 0.1 mg/Kg) of PN-SIA49 or the
control antibody (e137, 10 mg/Kg) were administrated to mice by
intraperitoneal injection in a final volume of 0.2 ml. A subset of six
mice in each group were weighed on the day of virus challenge
and then observed and weighed every 2 days for 2 weeks after
inoculation. Mice that lost more than 25% of their initial body
weight were euthanized.
A subset of four animals treated with mAbs were euthanized on
day 4 after inoculation, and whole lungs were homogenized in
1 ml of sterile PBS. Virus titers in lung tissue homogenates were
determined by plaque titration in MDCK cell monolayer cultures.
Definition of the region bound by PN-SIA49 on HA
Hemagglutination (HI) assay. HI tests using mAb PN-
SIA49 or e137 control antibody against live WS33 and VN04
viruses were performed according to standard protocols [38].
Briefly, serial dilutions of purified mAbs in PBS were performed
from initial concentration of 5 mg/mL. Positive and negative
control ferret sera were diluted initially 1:10 in receptor-destroying
enzyme from Vibrio cholerae (Denka Seiken, Tokyo). Serial
dilutions of control sera or mAbs were pre-incubated with 4 HA
units of virus per well. For WS33 virus, turkey red blood cells
(RBCs) were added to a final concentration of 0.5%, whereas
horse RBCs were used at a 1% suspension for VN04 virus. Normal
ferret serum gave a value of less than 10. Specific HI activity of
mAbs was calculated as the lowest concentration of mAb that
displayed HI activity.
Protease susceptibility assay. Each reaction contained 3 ml
of the anti-influenza vaccine season 2011–2012 (InflexalV-Crucell),
which contains 30 ng of A/California/7/09 (H1N1) HA or 3 mlo f
the anti-influenza vaccine season 2011–2012 combined with 2 fold
molar excess of PN-SIA49. Titron X-100 was added to prevent
aggregation of the post-fusion HA. The pH was lowered in all
samples except controls using citric acid 0.1 M pH 3. Reactions
weremixed,brieflycentrifuged and incubatedat 37uC foronehour.
After incubation, reactions were equilibrated to room temperature
and the pH was neutralized by addition of 1 M Tris, pH 9. The
actual pH reached was determined in parallel using larger buffer
volumes without protein. Trypsin was added to all samples except
controls at a final ratio of 1:25 by mass and samples were digested
overnight at 37uC. Non-reducing SDS buffer was added to each
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reducing 4–15% polyacrilamide pre-casted gel (Biorad, Italy). After
running, samples were transferred on a PVDF membrane
(PerkinElmer, Belgium) for 2 hours at 350 mA. The membrane
was then blocked with 5% not fat milk in PBS-Tween20 0,1%
(PBST) for 1 h at room temperature and then washed three times
with PBST. PN-SIA28, a human anti-HA monoclonal antibody
recognizing HA0 [39], was used as primary antibody at 1 mg/ml in
5% not fat milk-PBST. The membrane was incubated for 1 hour at
room temperature and then was washed three times with PBST.
Secondary anti-human antibody was added and incubated for 1 h
at room temperature. After incubation the membrane was washed,
the substrate solution (SuperSignalH West Pico Chemiluminescent
Substrate, PIERCE) was added and incubated for 2 min.
To determine the pH required to convert the HA to the post-
fusion form, pH titrations using the assay describing above was
performed. Samples were exposed to a range of pH conditions
(pH 4.5, 4.9, 5.3, 5.7, 6.1, 6.5, 7 and 8), neutralized and processed
as described above.
Hemagglutinin cloning and mutagenesis
A/Puerto Rico/8/1934 (H1N1) hemagglutinin (A/PR/8/34-
HA) was amplified as previously described [26,37] using the
following PCR primers:
APR834_fw:CACCATGAAGGCAAACC-
TACTGGTCCTGTTATGTG.
APR834_rev:TCAGATGCATATTCTGCACTGCAAA-
GATCCATTAGA.
The PCR products were cloned into the pcDNA 3.1D/V5-His-
TOPO vector (Invitrogen, Carlsbad, CA, USA). Subsequently,
HA alanine mutants were generated using Gene Tailor Site-
Directed Mutagenesis System (Invitrogen, Carlsbad, CA, USA). A
total of 20 A/PR/8/34-HA mutants were generated (His25Ala,
His45Ala, Thr315Ala, Asn336Ala, Ile337Ala, Pro338Ala on the
HA1 subunit and Trp357, Thr358, Gly359, Met360, Ile361,
Asp362, Gly363, Trp364, Thr384, Ile388, Thr392, Val395,
Asn396, Glu400 on the HA2 subunit. Sequence numbering refers
to A/PR/8/34, GenBank accession number ABO21709).
Cytofluorimetric binding assays
The binding activity of PN-SIA49 was assayed using full-length
wild type and mutants HAs. Human epithelial kidney HEK293T
cells (ATCC CRL-1573) were transfected in 6 wells plate
(Corning, Corning, NY, USA) (16106 cells/well) with 4 mgo f
pcDNA 3.1D/V5-His-TOPO vector containing the HA nucleo-
tide sequences described above. After centrifugation and fixation
with 4% paraformaldehyde for 15 minutes at RT, the transfected
cells were incubated for 30 minutes at room temperature with PN-
SIA49 or conformational controls for H1N1 (RB62) at 10 mg/ml.
Additionally, the isotype control, e137 (10 mg/ml) was introduced
as well as untransfected cells and a mouse anti-influenza A HA
(H1 subtype) monoclonal antibody (GeneTex Inc., Irvine, CA,
USA) directed against a linear epitope to evaluate the transfection
efficiency and the expression level for each HA. The cells were
then washed with PBS and incubated for 30 minutes at room
temperature with FITC-conjugated anti-human (Sigma Aldrich)
or anti-mouse (Argene, Shirley, NY, USA) antibody. Afterwards,
the cells were washed with PBS and analyzed by FACS. The
FACS data were analyzed using the software Weasel w 2.5
(Waler+Eliza Hall, Institute of Medical Research, Parkville
Victoria, Australia). The binding of PN-SIA49 to the different
HA-mutants was then expressed as a binding percentage
compared to wild-type. The data showing the PN-SIA 49 binding
decrease between H1N1 wild type HA and H1N1 HA mutants,
were obtained normalizing each PN-SIA 49 binding value to
corresponding anti-H1 expression control values.
For the competition assay, serial dilutions of PN-SIA49 were
used in combination with a fixed concentration (1 mg/ml) of
mouse monoclonal antibody C179 (Takara Bio inc., Otsu, Shiga,
Japan) which binds to an epitope on the HA stem region [29].
Software
For sequences analysis the following software packages were
used: SeqScape (Applied Biosystems), ClustalX (Toby Gibson), Bio
Edit (Tom Hall, Ibis Therapeutics) and Treeview (GubuSoft). For
molecular visualization and rendering UCSF Chimera package
from the Resource for Biocomputing Visualization and Informat-
ics at University of California, RasMol (Roger Sayle), Jmol (Jmol:
an open-source Java viewer for chemical structures in 3D. http://
www.jmol.org/), Cn3D (United States National Library of
Medicine, NLM) were used. Finally for data analysis and graphical
editing GraphPad Prism was used.
Supporting Information
Figure S1 Neutralization assays against group 1 influ-
enza viruses. Dose-response curve fit nonlinear regression is
reported for IgG PN-SIA49 against neutralized group 1 influenza
viruses. (A) Results from fluorescence inhibition assays, (B) plaque
reduction assays and (C) infectious foci formation reduction assays.
Data from at least two different experiments for each virus are
reported. Each point was performed in triplicate.
(PDF)
Figure S2 Influenza hemagglutinin unrooted phyloge-
netic tree of all the viral strains tested in neutralization
assays with PN-SIA49. Viral isolates belonging to group 1 and
group 2 are divided into two different boxes. Subtypes that can be
neutralized by PN-SIA49 are indicated with a green ‘+’, while the
ones that cannot be neutralized are indicate with a red ‘2’. As
reported in the text, PN-SIA49 is able to neutralize all of the group
1 viruses tested in this study except for the H9N2 strain. No
neutralizing activity was detected against the H3N2 viruses tested.
* The recombinant HA from A/South Carolina/1/1918 (H1N1)
pandemic strain was previously shown to be bound by PN-SIA49
[26,27]. # H1N1 A/New Caledonia/20/1999 was previously
shown to be neutralized by PN-SIA28 as Fab fragment [26,27].
(PDF)
Figure S3 C179/PN-SIA49 competition assay. Graphic
representation of cell staining and flow cytometric analysis of
HEK293T cells transfected with the pcDNA 3.1D/V5-His-
TOPO vector containing the HA-A/PR/8/34 were performed.
Serial dilutions of PN-SIA49 were used in combination with a
fixed concentration (1 mg/ml) of C179 (blue line). A monoclonal
antibody directed against the HA globular head was used as
competition negative control (pink line).
(PDF)
Figure S4 HA mutants that determine a decrease of PN-
SIA49 binding to HA are expressed at the same level of
wild type HA on cell surface. FACS curves showing the
binding of anti-H1N1 HA antibody (directed against a linear
epitope) to untransfected cells, HA wild-type and HA-mutants.
White and red curves represent, for each graph, respectively the
binding of anti-HA expression control to untransfected cells and
wild type H1N1-HA. The different colour curves represent the
different mutants.
(PDF)
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